NASDAQ · CCCC
Healthcare · Biotechnology
$3.43
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 8:32 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CCCC closed at $3.43 after 20 trading sessions, down 17.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.40 | $3.455 | $3.32 | $3.43 | 1.34M |
| Sep 14, 2026 | $3.46 | $3.54 | $3.41 | $3.43 | 1.49M |
| Sep 11, 2026 | $3.475 | $3.525 | $3.355 | $3.51 | 1.48M |
| Sep 10, 2026 | $3.40 | $3.41 | $3.31 | $3.40 | 1.17M |
| Sep 9, 2026 | $3.54 | $3.54 | $3.42 | $3.44 | 1.44M |
| Sep 8, 2026 | $3.72 | $3.735 | $3.55 | $3.55 | 2.17M |
| Sep 4, 2026 | $3.72 | $3.845 | $3.6604 | $3.76 | 2.36M |
| Sep 3, 2026 | $3.83 | $3.85 | $3.70 | $3.74 | 2.23M |
| Sep 2, 2026 | $3.87 | $4.07 | $3.73 | $3.79 | 1.84M |
| Sep 1, 2026 | $3.68 | $3.935 | $3.6602 | $3.87 | 2.36M |
| Aug 31, 2026 | $3.83 | $3.86 | $3.695 | $3.71 | 1.86M |
| Aug 28, 2026 | $4.07 | $4.10 | $3.83 | $3.85 | 1.83M |
| Aug 27, 2026 | $4.25 | $4.30 | $4.09 | $4.10 | 1.99M |
| Aug 26, 2026 | $4.17 | $4.24 | $4.03 | $4.24 | 1.86M |
| Aug 25, 2026 | $4.11 | $4.235 | $4.085 | $4.20 | 4.29M |
| Aug 24, 2026 | $3.97 | $4.14 | $3.81 | $4.10 | 1.75M |
| Aug 21, 2026 | $4.07 | $4.10 | $3.935 | $4.00 | 1.16M |
| Aug 20, 2026 | $4.14 | $4.15 | $3.832 | $4.03 | 2.27M |
| Aug 19, 2026 | $4.25 | $4.375 | $4.13 | $4.21 | 2.85M |
| Aug 18, 2026 | $4.21 | $4.30 | $4.105 | $4.18 | 2.88M |
The latest Smart Investors Daily articles mentioning CCCC.
CCCC research
Company profile and research snapshot.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 1, 2026 | Evercore ISI Group | Outperform | — |
| Feb 27, 2026 | Barclays | Overweight | — |
| Feb 23, 2026 | Brookline Capital | Buy | — |
| Dec 17, 2025 | Barclays | Overweight | — |
| Dec 2, 2025 | TD Cowen | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 5, 2026
C4 Therapeutics is a clinical-stage biopharmaceutical company that is pre-commercial but brings in revenue through partnerships. Read why CCCC stock is a hold.
Yahoo · Sep 3, 2026
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting. The data characterize the immune effect
Benzinga · Sep 3, 2026
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory
Yahoo · Aug 11, 2026
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CCCC.
